Pfizer (PFE) Minority Interest (2009 - 2026)

Pfizer has disclosed Minority Interest across 18 years of filings, most recently posting $303.0 million for Q1 2026.

• In Q1 2026, Minority Interest rose 1.34% year-over-year to $303.0 million; the TTM figure through Mar 2026 stood at $303.0 million (up 1.34% YoY), while the FY2025 annual figure was $299.0 million, up 1.7% from the prior year.
• Minority Interest rose to $303.0 million in Q1 2026, from $299.0 million in the prior quarter.
• Over the last five years, Minority Interest for PFE reached as high as $317.0 million in Q2 2025 and fell as low as $227.0 million in Q4 2022.
• The 5-year median for Minority Interest is $274.0 million (2023), against an average of $277.6 million.
• Annual changes were most pronounced in 2022 — Minority Interest decreased 18.64% — and 2023, when it grew 18.94%.
• A 5-year view of Minority Interest shows it stood at $256.0 million in 2022, then increased by 7.03% to $274.0 million in 2023, then gained by 7.3% to $294.0 million in 2024, then advanced by 1.7% to $299.0 million in 2025, then rose by 1.34% to $303.0 million in 2026.
• According to Business Quant data, Minority Interest over the past three periods registered $303.0 million, $299.0 million, and $295.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.